Ask a founder how they arrived at a £4m pre-money valuation for a company with no revenue and a six-person team, and the honest ones will tell you: they needed to raise £800,000, they didn't want to give away more than a fifth of the business, and a friend's company had just closed at a similar number. That's it. No spreadsheet survived contact with that decision. Early-stage valuation feels like it should be a calculation. It almost never is.
An early-stage startup valuation is the price a founder and an investor agree on for a slice of the company - set by negotiation, anchored to recent comparable deals and the mechanics of the round, not by any formula. The classic valuation tools - discounted cash flow, revenue multiples, profit multiples - need cash flows, revenue or profit to work with. A pre-seed company has none of those, or so little that the maths is meaningless. So the number gets built a different way.
Why there's no formula at seed
A valuation is meant to capture what a business is worth. For a mature company you can argue from its earnings: here's the cash it throws off, here's a sensible multiple, here's the value. For a startup with three customers and a prototype, there's nothing solid to multiply. What you're actually pricing is an option - the small chance of a very large outcome, discounted heavily for the overwhelming likelihood it doesn't get there.
That makes the number forward-looking and, frankly, speculative. It reflects belief about where the company could be in seven years, not what it is today. Two companies that look identical on paper can be priced a million pounds apart depending on the team's track record, how hot the sector is that quarter, and whether more than one investor wants in. Which is the real driver, and the one founders understand instinctively: at seed, valuation is supply and demand for a scarce asset.
At seed, the valuation prices the dream, discounted for the odds it stays one.
The methods angels and founders actually use
None of these produces a "correct" answer. Each is a structured way of defending a number you've already half-decided on. Used together, they keep the negotiation honest.
Comparables
The workhorse. What did similar companies - same stage, same sector, same rough geography - raise at recently, and at what valuation? A UK fintech raising its first institutional round looks at other UK fintech seed rounds from the past year. Comparables anchor everyone's expectations and stop a conversation drifting into fantasy. Their weakness is obvious: every startup claims to be unlike the others, and "comparable" deals are often a year stale and priced in a different market mood.
The round-size method
Quietly the most influential, because it's how the number usually gets set in practice. You work backwards from two figures the founder already has in mind: how much they need to raise, and how much of the company they're willing to give up to raise it. A founder raising £500,000 who'll part with 20% is implying a £2.5m post-money valuation - £500,000 is 20% of £2.5m - whether or not anyone says the word "valuation" out loud. Most seed founders aim to sell somewhere between 10% and 25% per round, so the dilution they'll tolerate effectively sets the price.
Scorecard and risk-factor frameworks
Angel networks often lean on these for pre-revenue deals. You take a typical valuation for the region and stage, then adjust it up or down against a checklist: strength of the founding team, size of the market, the product and its defensibility, early traction, competition, the need for further funding. The well-known versions - the Scorecard (or Berkus-style) method and the risk-factor summation method - dress the judgement in a grid, which helps a group of angels reach a shared number. It's still judgement. The grid just makes the assumptions visible enough to argue about.
Or: dodge the question entirely
A lot of the earliest money goes in without pricing the company at all. Convertible instruments - in the UK, often an advance subscription agreement (an ASA, which can be structured to preserve SEIS or EIS eligibility), or an American-style SAFE - postpone the valuation to the next priced round. Instead of a price, they set a valuation cap: a ceiling on the valuation at which your money converts into shares. It lets a deal close fast when neither side wants to fight over a number yet, and hands the early investor some of the upside if the next round prices higher than the cap.
What the number does to your stake
Here's the part that matters once the handshake is done. Your ownership is your cheque divided by the post-money valuation - the pre-money figure plus the new money raised. Put £100,000 into a round with a £2.5m post-money valuation and you own 4%. The valuation isn't an abstraction; it's the denominator that decides your slice.
Which is why a higher valuation isn't automatically good news for the person writing the cheque. Pay £100,000 at a £5m post-money and you own 2% for the same money. The headline looks more impressive and the founder is happier, but you bought half as much company. A high entry price also sets a high bar: the company now has to grow into that number before a later round can clear above it. Price a seed too aggressively and you risk a flat or down round next time, with the anti-dilution clauses and dented morale that come with it. The number that serves everyone is the one the business can realistically grow past - not the biggest one a founder can extract in a hot moment.
Does the valuation change your SEIS or EIS relief?
No - and let's be clear about it, because the two often get tangled. SEIS and EIS income tax relief is calculated on the amount you actually subscribe for eligible shares, not on the company's valuation or how the round was framed. SEIS gives 50% income tax relief on up to £200,000 of investment per tax year; EIS gives 30% on up to £1,000,000 per tax year, or £2,000,000 if at least £1,000,000 goes into knowledge-intensive companies. Both carry a minimum three-year holding period, both need the company to have HMRC advance assurance before the round, and both require the company to issue you an SEIS3 or EIS3 certificate before you can claim. The reliefs are generally available only to UK taxpayers.
The company-side eligibility rules - gross-asset ceilings, how old the company can be, and how much it can raise in total under each scheme - are tighter, and some have moved over time, so it's worth checking the current thresholds on gov.uk's EIS guidance rather than relying on a number you half-remember. The takeaway for valuation is simpler: a higher valuation shrinks the percentage your money buys, but it doesn't touch your relief, which tracks what you subscribe.
None of this is a view on whether any particular round is priced fairly or deserves your money - that's a judgement only you, and ideally an FCA-regulated adviser, can make. What it gives you is the ability to hear a founder say "four million" and know which questions decide whether that's a fair price or a stretch.
Early-stage valuations: quick answers
How is an early-stage startup valuation actually calculated?
At the earliest stages it usually isn't calculated in any formula sense. A seed or pre-seed valuation is set by negotiation: the founder names a number, the lead investor pushes back using comparable deals and how much the round needs to raise without giving away too much equity, and the two meet somewhere. Discounted cash flow and revenue multiples rarely apply because there is little or no revenue. The number is a price the market will bear for a slice of the company, anchored to recent deals of similar stage, sector and geography.
What methods are used to value a startup with no revenue?
Common approaches include comparables (what similar companies raised at recently), the round-size method (working back from how much the founder needs and how much dilution they will accept), and qualitative scorecard or risk-factor frameworks that adjust a regional average up or down for the team, market, product and traction. Convertible instruments such as SAFEs and advance subscription agreements often defer the question entirely by setting a valuation cap rather than a fixed price. None of these is precise; they are structured ways of arriving at a defensible number.
Why are seed-stage valuations so high relative to revenue?
Because the price reflects future potential and competition for the round, not current trading. A seed valuation prices the option on a large outcome, discounted heavily for the high chance of failure. When several investors want in, the founder holds the upper hand and the number rises. When money is scarce, valuations fall. It is supply and demand for a scarce asset more than a measure of present worth, which is why two similar companies can be priced very differently a year apart.
Does a higher valuation always benefit the investor?
No. A higher valuation buys you a smaller percentage of the company for the same cheque, and it raises the bar the company must clear before the next round can be priced higher. Pay too much at seed and you risk a flat or down round later, which can trigger anti-dilution clauses and erode confidence. A lower entry price means more ownership and more headroom, though founders naturally resist it. The right number balances ownership against the company's ability to grow into it.
Does the valuation change my SEIS or EIS tax relief?
No. SEIS and EIS income tax relief is calculated on the amount you subscribe for eligible shares, not on the company's valuation. SEIS gives 50% income tax relief on up to £200,000 per tax year and EIS gives 30% on up to £1,000,000 per tax year, or £2,000,000 where at least £1,000,000 goes into knowledge-intensive companies. Both require HMRC advance assurance and an SEIS3 or EIS3 certificate, and carry a minimum three-year holding period. Valuation decides how much of the company your money buys, not how much relief it attracts. This is general information, not financial advice.